Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06919328 · ClinicalTrials.gov registry record · NA

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

A NA study of Healthy Aging, sponsored by Nutraceuticals Research Institute.

Recruiting
Registry status
NA
Development phase
70
Enrollment target
1
Study location

NCT06919328 is a NA study of Healthy Aging that is actively recruiting participants, run by Nutraceuticals Research Institute. The registered enrollment target is 70 participants, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06919328, a NA study of Healthy Aging, is actively recruiting participants, sponsored by Nutraceuticals Research Institute.

RECRUITING
Registry status
NA
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Niagen®
  • OTHER NAD+

Study Locations (1)

Alabama

  • Nutraceuticals Research Institute - Huntsville

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2024-10-31
Est. Completion 2025-06-30
Phase NA

Sponsor

Nutraceuticals Research Institute

15 total trials

What the Registry Record Tells You About NCT06919328

The ClinicalTrials.gov registry entry for NCT06919328 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 40 other Healthy Aging trials with a reported enrollment target (42% lower). The listed sponsor is Nutraceuticals Research Institute, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Aging appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06919328 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.

Frequently Asked Questions

What is clinical trial NCT06919328 about?

NCT06919328 is a clinical study titled "Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+". This study evaluates the subjective effects of injection administration of NR on healthy adult populations.

What is the current status of trial NCT06919328?

This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-10-31. Estimated completion is 2025-06-30.

What conditions does trial NCT06919328 study?

This clinical trial studies the following conditions: Healthy Aging.

What interventions are being tested in trial NCT06919328?

The interventions under investigation include: Placebo (OTHER), Niagen® (DIETARY_SUPPLEMENT), NAD+ (OTHER).

Who is sponsoring clinical trial NCT06919328?

This trial is sponsored by Nutraceuticals Research Institute, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06919328 being conducted?

This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Aging

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.